-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, UHInldmamBIeCIOp3Cf0hyl/N6b27JRomfoBZDiGwDZ+fBMUP2Ous0ln5qOEDtIO IPeIBTaewwFnXuP0mRiFpQ== 0000950135-96-005270.txt : 19961212 0000950135-96-005270.hdr.sgml : 19961212 ACCESSION NUMBER: 0000950135-96-005270 CONFORMED SUBMISSION TYPE: SC 13D PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 19961211 SROS: NONE SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: MERIDIAN MEDICAL TECHNOLOGIES INC CENTRAL INDEX KEY: 0000095676 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 520898764 STATE OF INCORPORATION: DE FISCAL YEAR END: 0731 FILING VALUES: FORM TYPE: SC 13D SEC ACT: 1934 Act SEC FILE NUMBER: 005-35771 FILM NUMBER: 96679023 BUSINESS ADDRESS: STREET 1: 10240 OLD COLUMBIA ROAD CITY: COLUMBIA STATE: MD ZIP: 21046 BUSINESS PHONE: 4103096830 MAIL ADDRESS: STREET 1: 10240 OLD COLUMBIA ROAD CITY: COLUMBIA STATE: DE ZIP: 21046- FORMER COMPANY: FORMER CONFORMED NAME: SURVIVAL TECHNOLOGY INC DATE OF NAME CHANGE: 19920703 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: COMMONWEALTH BIOVENTURES INC CENTRAL INDEX KEY: 0000900884 STANDARD INDUSTRIAL CLASSIFICATION: [] IRS NUMBER: 042984136 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D BUSINESS ADDRESS: STREET 1: 4 MILK ST CITY: PORTLAND STATE: ME ZIP: 04101 BUSINESS PHONE: 2077800904 MAIL ADDRESS: STREET 1: 4 MILK ST CITY: PORTLAND STATE: ME ZIP: 04101 SC 13D 1 MERIDIAN MEDICAL TECHNOLOGIES, INC. 1 ---------------------------- OMB APPROVAL ---------------------------- OMB Number: 3235-0145 UNITED STATES Expires: October 31, 1997 SECURITIES AND EXCHANGE COMMISSION Estimated average burden WASHINGTON, D.C. 20549 hours per response ....14.90 ---------------------------- SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. __________)* Meridian Medical Technologies, Inc. - -------------------------------------------------------------------------------- (Name of Issuer) Common Stock - -------------------------------------------------------------------------------- (Title of Class of Securities) 589658103 ------------------------------------------------------- (CUSIP Number) Robert G. Foster 4 Milk Street Portland ME 04101 (207) 780-0904 - -------------------------------------------------------------------------------- (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) November 20, 1996 ------------------------------------------------------- (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(b)(3) or (4), check the following box [ ]. Check the following box if a fee is being paid with the statement [ ]. (A fee is not required only if the reporting person: (1) has a previous statement on file reporting beneficial ownership of more than five percent of the class of securities described in Item 1; and (2) has filed no amendment subsequent thereto reporting beneficial ownership of five percent or less of such class.) (See Rule 13d-7.) NOTE: Six copies of this statement, including all exhibits, should be filed with the Commission. See Rule 13d-1(a) for other parties to whom copies are to be sent. *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). 2 SCHEDULE 13D - ------------------- ------------------- CUSIP NO. 589658103 PAGE____OF____PAGES - ------------------- ------------------- - -------------------------------------------------------------------------------- 1 NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Commonwealth Bioventures Inc. - -------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ ] (b) [X] - -------------------------------------------------------------------------------- 3 SEC USE ONLY - -------------------------------------------------------------------------------- 4 SOURCE OF FUNDS* 00 - -------------------------------------------------------------------------------- 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO [ ] ITEMS 2(d) or 2(e) - -------------------------------------------------------------------------------- 6 CITIZENSHIP OR PLACE OF ORGANIZATION Massachusetts - -------------------------------------------------------------------------------- 7 SOLE VOTING POWER NUMBER OF 0 SHARES ------------------------------------------------------------- BENEFICIALLY 8 SHARED VOTING POWER OWNED BY 583,003* EACH ------------------------------------------------------------- REPORTING 9 SOLE DISPOSITIVE POWER PERSON 0 WITH ------------------------------------------------------------- 10 SHARED DISPOSITIVE POWER 583,003* - -------------------------------------------------------------------------------- 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 583,003* - -------------------------------------------------------------------------------- 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* [ ] - -------------------------------------------------------------------------------- 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 19.9% - -------------------------------------------------------------------------------- 14 TYPE OF REPORTING PERSON* CO *Beneficial ownership expressly disclaimed. - -------------------------------------------------------------------------------- *SEE INSTRUCTIONS BEFORE FILLING OUT! INCLUDE BOTH SIDES OF THE COVER PAGE, RESPONSES TO ITEMS 1-7 (INCLUDING EXHIBITS) OF THE SCHEDULE AND THE SIGNATURE ATTESTATION. 2 of 7 3 Schedule 13D Commonwealth Bioventures, Inc. ITEM 1. SECURITY AND ISSUER. The class of securities to which this Schedule relates is Common Stock, $.10 par value of Meridian Medical Technologies, Inc. (f/k/a Survival Technology, Inc.), a Delaware corporation (the "Issuer"). The address of the principal executive office of the Issuer is: Meridian Medical Technologies, Inc. 10240 Old Columbia Road Columbia, MD 21048 ITEM 2. IDENTITY AND BACKGROUND. The reporting person's name is Commonwealth BioVentures, Inc., a Massachusetts corporation, with a principal business and office address of 4 Milk Street, Portland, ME 04101. The reporting person's principal business is that of the general partner of a limited partnership that is the manager of three venture capital funds. During the last five years, the reporting person has not been convicted in a criminal proceeding (excluding traffic violations and similar misdemeanors). During the last five years, the reporting person has not been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding been or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws. ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION. The reporting person may be deemed to have acquired beneficial ownership of more than five percent of the Common Stock of the Issuer as a result of the Merger (defined in Item 4 below) in exchange for securities of Brunswick Biomedical Corporation, a Massachusetts corporation ("BBC") owned by three limited partnerships of which the reporting person is the general partner of the general partner. However, beneficial ownership by the reporting person is expressly disclaimed. ITEM 4. PURPOSE OF TRANSACTION. On November 20, 1996, pursuant to an Agreement and Plan of Merger dated as of September 11, 1996, BBC merged with and into Survival Technology, Inc. ("STI"), with STI as the surviving corporation (the "Merger"). Immediately following the Merger, STI changed its name to "Meridian Medical Technologies, Inc." 3 4 In accordance with the terms of the Merger, each share of BBC common stock was exchanged for 2.1 shares of Common Stock of the Issuer, and each share of BBC preferred stock was exchanged for 2.1 shares of Common Stock of the Issuer and a warrant to purchase 0.4 shares of Common Stock of the Issuer (the "Merger Warrant"). The Merger Warrants have an exercise price of $11.00 per share of Common Stock and are exercisable for five years following the closing of the Merger. In connection with the Merger, the Issuer also assumed the obligations of BBC under outstanding stock options and warrants. Each of the former BBC security holders has certain rights to registration with respect to the Common Stock under the Securities Act of 1933, as amended. The securities of the Issuer which the reporting person may be deemed to beneficially own are held for investment purposes by their respective owners (see description in Item 5 below). By virtue of its position as general partner of BioVenture Partners Limited Partnership, a Delaware limited partnership, the general partner of these entities ("BPLP"), the reporting person may continue to acquire, for investment purposes, or dispose of securities of the Issuer beneficially owned by it in the ordinary course of the reporting person's business. The reporting person expressly disclaims beneficial ownership. ITEM 5. INTEREST IN SECURITIES OF THE ISSUER. (a) The number of securities of the Issuer which the reporting person may be deemed to beneficially own is 583,003. Of those, 184,888 represent securities which the reporting person may be deemed to have the right to acquire within 60 days. This aggregate represents approximately 19.9% of the Issuer's outstanding class of such securities. The reporting person expressly disclaims beneficial ownership of all securities reported in this Schedule. (b) The reporting person does not have the sole power to vote and the sole power to dispose of any of the shares of the Issuer's securities. By virtue of its position as general partner of BPLP, the reporting person may be deemed to share the power to vote and share the power to dispose of the following common stock of the Issuer with BPLP and the entities so indicated: (i) 103,052 shares with Commonwealth BioVentures III Limited Partnership ("Fund III"); (ii) 140,383 shares with Commonwealth BioVentures IV Limited Partnership ("Fund IV"); and (iii) 339,568 shares with Commonwealth BioVentures V Limited Partnership ("Fund V"). However, the reporting person expressly disclaims beneficial ownership of these shares. The business address of BPLP, Fund III, Fund IV and Fund V is 4 Milk Street, Portland, ME 04101. Fund III, Fund IV and Fund V are venture capital funds and BPLP is their general partner. None of BPLP, Fund III, Fund IV or Fund V during the last five years, have been convicted in a criminal proceeding (excluding traffic violations and similar misdemeanors) nor have and of them been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding been 4 5 or are subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws. (c) Other than the acquisitions resulting from the Merger described in Item 4, the reporting person has not effected any transactions in the securities of the Issuer in the last sixty days. (d) Except as otherwise indicated in this Schedule, no other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities. (e) Not Applicable. ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER. There are no contracts, arrangements, understandings or relationships among the reporting person and any other person with respect to the securities of the Issuer. ITEM 7. MATERIAL TO BE FILED AS EXHIBITS. None. SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. COMMONWEALTH BIOVENTURES, INC. BY: - ------------------------------- ----------------------------------- Date Robert G. Foster, President 5 -----END PRIVACY-ENHANCED MESSAGE-----